Skip to content

Nasdaq · CIK 0002056611

LTGO Latigo Biotherapeutics, Inc.

Insider trading from SEC Form 4. Last filing Aug 12, 2026. Close $16.02 on Oct 12, 2026, +8% from the 52-week low and -36% from the high.

In brief

Latigo Biotherapeutics, Inc. (LTGO) has 7 SEC Form 4 filings on file from 7 insiders, the latest filed on Aug 12, 2026. In the last 90 days insiders made 2 open-market buys worth $5.0M and 0 open-market sells worth $0, net +$5.0M.

2 open-market trades have been scored at LTGO. The newest: Foresite Capital Management V, LLC (10% owner) bought $2.5M of stock on Aug 10, 2026, filed Aug 10, 2026, scored 43 (moderate). 2 insiders bought within 14 days of each other around Aug 10, 2026.

Last 90 days

Net insider value
+$5.0M
more bought than sold
Buys
2
$5.0M by 2 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company

Price and insider trades, last year

LTGOOct 12, 2026 · close 16.02

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Latigo Biotherapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
43ModerateForesite Capital Management V, LLC
owner
buy
$2.5M
140,000 shares
+7%-
51ModerateJames B. Tananbaum
director, owner
buy
$2.5M
140,000 shares
+7%-

Transactions

The newest 50 of 69 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Aug 10, 2026Sanofi
owner
CConversion
Common Stockindirect: See footnote
+494,800--494,800Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Common Stockindirect: By 5AM Ventures VI, L.P.
+4,975,543--4,975,543Aug 12, 2026
Aug 10, 2026Sanofi
owner
CConversion
Common Stockindirect: See footnote
+177,978--672,788Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Common Stockindirect: By 5AM Opportunities II, L.P.
+2,350,419--2,350,419Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Series A Preferred Stockderivativeindirect: By 5AM Ventures VI, L.P.
-3,152,305$0.00$00Aug 12, 2026
Aug 10, 2026Sanofi
owner
CConversion
Series B Preferred Stockderivativeindirect: See footnote
-494,800--0Aug 12, 2026
Aug 10, 2026Sanofi
owner
CConversion
Convertible Promissory Notederivativeindirect: See footnote
-177,978--0Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Series A-2 Preferred Stockderivativeindirect: By 5AM Ventures VI, L.P.
-1,823,238$0.00$00Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Series A-2 Preferred Stockderivativeindirect: By 5AM Opportunities II, L.P.
-866,018$0.00$00Aug 12, 2026
Aug 10, 20265AM Ventures VI, L.P.
owner
CConversion
Series B Preferred Stockderivativeindirect: By 5AM Opportunities II, L.P.
-1,484,401$0.00$00Aug 12, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+938,979--1,368,532Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+3,547,842--4,916,374Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+1,027,635--5,944,009Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+3,464,072--3,510,927Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+1,484,401--4,995,328Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+165,519--5,160,847Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Common Stockindirect: See footnote
+2,066,857--2,094,813Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series Seed Convertible Preferred Stockderivativeindirect: See footnote
-938,979--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series A Convertible Preferred Stockderivativeindirect: See footnote
-3,547,842--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series A-2 Convertible Preferred Stockderivativeindirect: See footnote
-1,027,635--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series A-2 Convertible Preferred Stockderivativeindirect: See footnote
-3,464,072--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series B Convertible Preferred Stockderivativeindirect: See footnote
-1,484,401--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Series A-2 Convertible Preferred Stockderivativeindirect: See footnote
-2,066,857--0Aug 11, 2026
Aug 10, 2026Westlake BioPartners Fund I, L.P.
owner
CConversion
Convertible Promissory Notederivativeindirect: See footnote
-165,519--0Aug 11, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+3,117,664--3,117,664Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+938,979--1,368,532Aug 10, 2026
Aug 6, 2026Todd N Smith
director
AGrant or award
Director Stock Option (right to buy)derivative
+105,542$0.00$0105,542Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+3,117,664$0.00$03,117,664Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+445,320$0.00$03,562,984Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+445,320--3,562,984Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+3,547,842--4,916,374Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+1,125,823--1,125,823Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+1,125,823$0.00$01,125,823Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+1,027,635--5,944,009Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+742,201--1,868,024Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+742,201$0.00$01,868,024Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+3,464,072--3,510,927Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
POpen-market purchase
Common Stockindirect: See footnote
+140,000$18.00$2.5M2,008,024Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
POpen-market purchase
Common Stockindirect: See Footnote
+140,000$18.00$2.5M2,008,024Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+1,484,401--4,995,328Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+195,776--2,203,800Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+195,776--2,203,800Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+165,519--5,160,847Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+3,117,664--3,117,664Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+3,117,664$0.00$03,117,664Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Common Stockindirect: See footnote
+2,066,857--2,094,813Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Common Stockindirect: See footnote
+296,880--3,414,544Aug 10, 2026
Aug 10, 2026Foresite Capital Management V, LLC
owner
CConversion
Common Stockindirect: See Footnote
+296,880$0.00$03,414,544Aug 10, 2026
Aug 10, 2026Beth C Seidenberg
director, owner
CConversion
Series Seed Convertible Stockderivativeindirect: See footnote
-938,979--0Aug 10, 2026
Aug 10, 2026James B. Tananbaum
director, owner
CConversion
Series A-2 Convertible Stockderivativeindirect: See footnote
-3,117,664--0Aug 10, 2026
50 of 69 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about LTGO

Answered from the filings on this page, as of the latest one.

Are insiders buying LTGO?

As of Aug 12, 2026, SEC Form 4 filings show 2 open-market buys worth $5.0M by 2 insiders and 0 open-market sells worth $0 by 0 insiders at Latigo Biotherapeutics, Inc. in the last 90 days, net +$5.0M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.

Who was the last insider to trade LTGO on the open market?

Foresite Capital Management V, LLC (10% owner) bought $2.5M of LTGO on Aug 10, 2026 and filed the Form 4 on Aug 10, 2026. InsiderTell scored 43 (moderate), with 2 insiders on the same side within 14 days.

How many insiders file Form 4 at Latigo Biotherapeutics, Inc.?

7 people have filed a Form 4 at Latigo Biotherapeutics, Inc., among them 5AM Ventures VI, L.P. (10% owner), Foresite Capital Management V, LLC (10% owner), Beth C Seidenberg (director and 10% owner). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

LTGO insider trading: Latigo Biotherapeutics, Inc. | InsiderTell